INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 128 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2016. The put-call ratio across all filers is 3.16 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $66,727 | -60.7% | 1,281 | -52.3% | 0.00% | -66.7% |
| Q2 2023 | $169,951 | +147683.5% | 2,684 | +26.5% | 0.01% | +50.0% |
| Q1 2023 | $115 | +150.0% | 2,121 | +146.3% | 0.00% | +100.0% |
| Q4 2022 | $46 | -100.0% | 861 | -86.3% | 0.00% | -60.0% |
| Q3 2022 | $291,000 | +28.8% | 6,263 | +57.9% | 0.01% | 0.0% |
| Q2 2022 | $226,000 | +205.4% | 3,966 | +230.8% | 0.01% | +400.0% |
| Q1 2022 | $74,000 | -28.8% | 1,199 | -39.8% | 0.00% | -50.0% |
| Q4 2021 | $104,000 | -4.6% | 1,991 | -32.2% | 0.00% | -33.3% |
| Q3 2021 | $109,000 | -18.0% | 2,937 | -9.7% | 0.00% | 0.0% |
| Q2 2021 | $133,000 | -52.3% | 3,253 | -60.5% | 0.00% | -40.0% |
| Q1 2021 | $279,000 | +220.7% | 8,241 | +199.9% | 0.01% | +66.7% |
| Q4 2020 | $87,000 | -82.2% | 2,748 | -85.6% | 0.00% | -40.0% |
| Q3 2020 | $488,000 | +154.2% | 19,044 | +154.9% | 0.01% | -37.5% |
| Q2 2020 | $192,000 | +4700.0% | 7,471 | +1394.2% | 0.01% | – |
| Q3 2019 | $4,000 | -83.3% | 500 | -73.5% | 0.00% | -100.0% |
| Q2 2019 | $24,000 | -53.8% | 1,885 | -55.4% | 0.00% | -33.3% |
| Q1 2019 | $52,000 | +300.0% | 4,225 | +265.2% | 0.00% | +200.0% |
| Q4 2018 | $13,000 | -80.6% | 1,157 | -62.4% | 0.00% | -80.0% |
| Q3 2018 | $67,000 | +3.1% | 3,078 | -24.8% | 0.01% | 0.0% |
| Q3 2017 | $65,000 | +1525.0% | 4,091 | +1103.2% | 0.01% | – |
| Q2 2017 | $4,000 | -95.4% | 340 | -94.1% | 0.00% | -100.0% |
| Q4 2016 | $87,000 | +141.7% | 5,762 | +142.1% | 0.01% | +125.0% |
| Q3 2016 | $36,000 | +227.3% | 2,380 | +712.3% | 0.00% | +300.0% |
| Q2 2016 | $11,000 | -8.3% | 293 | -31.9% | 0.00% | -50.0% |
| Q1 2016 | $12,000 | -88.7% | 430 | -78.3% | 0.00% | -88.2% |
| Q4 2015 | $106,000 | +241.9% | 1,979 | +51.1% | 0.02% | +325.0% |
| Q1 2015 | $31,000 | +675.0% | 1,310 | +555.0% | 0.00% | – |
| Q4 2014 | $4,000 | -96.8% | 200 | -97.8% | 0.00% | -100.0% |
| Q3 2014 | $125,000 | +95.3% | 9,152 | +140.5% | 0.01% | +75.0% |
| Q2 2014 | $64,000 | +481.8% | 3,806 | +541.8% | 0.01% | +700.0% |
| Q1 2014 | $11,000 | – | 593 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |